ALDX

Aldeyra Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth 4/10
  • Value 5/10
Aldeyra Therapeutics sales and earnings growth
ALDX Growth
Neutral
  • Revenue Y/Y 0.00%
  • EPS Y/Y 40.43%
  • FCF Y/Y 22.83%
Aldeyra Therapeutics gross and profit margin trends
ALDX Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y -400.59%
Aldeyra Therapeutics net debt vs free cash flow
ALDX Risk
Great
  • Debt / Equity 0.4
  • Debt / FCF 0.0
  • Interest coverage -16.8

Aldeyra Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗